Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

• Status: Not yet recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xuanwu Hospital, Beijing
• Treatments: Dimethyl Fumarate

Criteria

Inclusion Criteria:

1.18-80 years old 2. NIHSS score>6 3. For the first stroke, MRI showed anterior circulation infarction 4. Patients who meet the mechanical thrombectomy treatment by MRI assessment within 24 hours

Exclusion Criteria:

1. Patients receiving Alteplase thrombolysis

2. Other diseases of the central nervous system

3. There has been a neurological disability in the past (mRS score>2)

4. Difficulty swallowing

5. Arrhythmia, atrioventricular block

6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs

7. Macular edema

8. Magnetic resonance angiography shows vertebra-basilar artery obstruction

9. Hemorrhagic stroke

10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product

11. Pregnant and lactating women